{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:21:23Z","timestamp":1779909683055,"version":"3.53.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003654.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000}}],"reference-count":135,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003654.pub5","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T22:45:21Z","timestamp":1634769921000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Calcium channel blockers versus other classes of drugs for hypertension"],"prefix":"10.1002","volume":"2021","author":[{"given":"Jiaying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muke","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cairong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Epidemic Disease & Health Statistics Department; School of Public Health, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Ma","sequence":"additional","affiliation":[{"name":"China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurology; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"issue":"21","key":"10.1002\/14651858.CD003654.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1016\/S0197-2456(97)82681-5","article-title":"Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study","volume":"16","author":"Kusek","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"5","key":"10.1002\/14651858.CD003654.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial","volume":"48","author":"Norris","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"19","key":"10.1002\/14651858.CD003654.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003654.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0197-2456(96)00081-5","article-title":"Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study","volume":"17","author":"Wright","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"10","key":"10.1002\/14651858.CD003654.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0007|cit7","unstructured":"Savage S Johnson Nagel N Estacio RO Feig PU MacCarthy EP Lukken NJ The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes Online Journal of Current Clinical Trials Doc No 104"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJM200012283432614","article-title":"Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension","volume":"343","author":"Schrier","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003654.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1751-7176.2011.00568.x","article-title":"Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"14","author":"Cushman","year":"2012","journal-title":"Journal of Clinical Hypertension"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD003654.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0895-7061(96)00037-4","article-title":"Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"9","author":"Davis","year":"1996","journal-title":"American Journal of Hypertension"},{"issue":"23","key":"10.1002\/14651858.CD003654.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD003654.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","article-title":"Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"19","author":"Sever","year":"2001","journal-title":"Journal of Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD003654.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1291\/hypres.26.979","article-title":"Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods","volume":"26","author":"Fukui","year":"2003","journal-title":"Hypertension Research"},{"issue":"2","key":"10.1002\/14651858.CD003654.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","article-title":"Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial","volume":"51","author":"Ogihara","year":"2008","journal-title":"Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD003654.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/hr.2011.120","article-title":"Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex)","volume":"34","author":"Ogihara","year":"2011","journal-title":"Hypertension Research"},{"issue":"16","key":"10.1002\/14651858.CD003654.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD003654.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.HYP.37.1.12","article-title":"Baseline characteristics and early blood pressure control in the CONVINCE trial","volume":"37","author":"Black","year":"2001","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD003654.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0197-2456(98)00013-0","article-title":"Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial","volume":"19","author":"Black","year":"1998","journal-title":"Controlled Clinical Trials"},{"issue":"19","key":"10.1002\/14651858.CD003654.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD003654.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"Tatti","year":"1998","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD003654.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/hr.2012.125","article-title":"Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure","volume":"35","author":"Asayama","year":"2012","journal-title":"Hypertension Research"},{"issue":"7","key":"10.1002\/14651858.CD003654.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD003654.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"245","author":"Lewis","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003654.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ndt\/15.4.487","article-title":"The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics","volume":"15","author":"Rodby","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9227","key":"10.1002\/14651858.CD003654.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"issue":"21","key":"10.1002\/14651858.CD003654.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD003654.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(98)00423-9","article-title":"Rationale and design of the International Verapamil SR\/Trandolapril Study (INVEST)","volume":"32","author":"Pepine","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD003654.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1291\/hypres.27.181","article-title":"Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial","volume":"27","author":"Yui","year":"2004","journal-title":"Hypertension Research"},{"issue":"10","key":"10.1002\/14651858.CD003654.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.1996.03540100029024","article-title":"Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial","volume":"276","author":"Borhani","year":"1996","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003654.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00005344-199200193-00005","article-title":"MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis","volume":"19","author":"Borhani","year":"1992","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"Suppl 4A","key":"10.1002\/14651858.CD003654.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(89)90188-5","article-title":"Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)","volume":"86","author":"Furberg","year":"1989","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003654.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jjcc.2010.03.004","article-title":"Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance","volume":"56","author":"Matsushita","year":"2010","journal-title":"Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD003654.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/HYPERTENSIONAHA.111.184226","article-title":"Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study","volume":"59","author":"Muramatsu","year":"2012","journal-title":"Hypertension"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD003654.pub5-BIB0036|cit36","first-page":"S35","article-title":"Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives","volume":"12","author":"Kuramoto","year":"1994","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD003654.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.HYP.34.5.1129","article-title":"Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives","volume":"34","author":"National Intervention Cooperative Study in Elderly Hypertensives Study Group","year":"1999","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and \u03b2-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"issue":"5-6","key":"10.1002\/14651858.CD003654.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/080370599439517","article-title":"Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients","volume":"8","author":"Hedner","year":"1999","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/08037059309077174","article-title":"The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension","volume":"2","author":"NORDIL Study Group","year":"1993","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08037050310009545","article-title":"Treatment of isolated systolic hypertension: The SHELL Study results","volume":"12","author":"Malacco","year":"2003","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3109\/08037059309077541","article-title":"STOP-Hypertension-2: a prospective intervention trial of \"newer\" versus \"older\" treatment alternatives in old patients with hypertension","volume":"2","author":"Dahl\u00f6f","year":"1993","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/08037059609078063","article-title":"The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report","volume":"5","author":"Lindholm","year":"1996","journal-title":"Blood Pressure"},{"issue":"9","key":"10.1002\/14651858.CD003654.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/0002-9149(90)90760-X","article-title":"The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline","volume":"66","author":"Mascioli","year":"1990","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.1993.03510060059034","article-title":"Treatment of Mild Hypertension Study: final results","volume":"270","author":"Neaton","year":"1993","journal-title":"JAMA"},{"issue":"14","key":"10.1002\/14651858.CD003654.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"51G","DOI":"10.1016\/0002-9149(87)90158-5","article-title":"Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS)","volume":"59","author":"Stamler","year":"1987","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.1991.00400070161023","article-title":"The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies","volume":"151","author":"The Treatment of Mild Hypertension Research Group","year":"1991","journal-title":"Archives of Internal Medicine"},{"issue":"9426","key":"10.1002\/14651858.CD003654.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003654.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/080370598437394","article-title":"The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design","volume":"7","author":"Mann","year":"1998","journal-title":"Blood Pressure"},{"issue":"1","key":"10.1002\/14651858.CD003654.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/hr.2010.186","article-title":"Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial","volume":"34","author":"Narumi","year":"2011","journal-title":"Hypertension Research"},{"issue":"11","key":"10.1002\/14651858.CD003654.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/00004872-199715110-00019","article-title":"Clinical results of the Verapamil in Hypertension and Atherosclerosis Study","volume":"15","author":"Rosei","year":"1997","journal-title":"Journal of Hypertension"},{"issue":"11","key":"10.1002\/14651858.CD003654.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/00004872-199816110-00014","article-title":"The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness","volume":"16","author":"Zanchetti","year":"1998","journal-title":"Journal of Hypertension"},{"issue":"17","key":"10.1002\/14651858.CD003654.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/archinte.158.17.1882","article-title":"Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart Study","volume":"158","author":"Abascal","year":"1998","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00380-012-0274-1","article-title":"L\/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease","volume":"28","author":"Abe","year":"2013","journal-title":"Heart Vessels"},{"issue":"23","key":"10.1002\/14651858.CD003654.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003654.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ki.1996.480","article-title":"Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy","volume":"50","author":"Bakris","year":"1996","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.HYP.29.3.744","article-title":"Effect of calcium channel or \u03b2-blockade on the progression of diabetic nephropathy in African Americans","volume":"29","author":"Bakris","year":"1997","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD003654.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e013672","DOI":"10.1136\/bmjopen-2016-013672","article-title":"Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial","volume":"7","author":"Xue","year":"2017","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0091270010376963","article-title":"Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension","volume":"51","author":"Bhad","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1185\/03007995.2013.803057","article-title":"Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension","volume":"29","author":"Calhoun","year":"2013","journal-title":"Current Medical Research and Opinion"},{"issue":"12","key":"10.1002\/14651858.CD003654.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/hr.2011.120","article-title":"Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex)","volume":"34","author":"Ogihara","year":"2011","journal-title":"Hypertension Research"},{"issue":"3","key":"10.1002\/14651858.CD003654.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"e57854","DOI":"10.1371\/journal.pone.0057854","article-title":"The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0064|cit64","first-page":"113","article-title":"Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice","volume":"34","author":"Cicero","year":"2012","journal-title":"Clinical & Experimental Hypertension (New York)"},{"issue":"10","key":"10.1002\/14651858.CD003654.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","article-title":"Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial","volume":"32","author":"Ogihara","year":"2014","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD003654.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","article-title":"Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial","volume":"58","author":"Ruggenenti","year":"2011","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.jhh.1000406","article-title":"Calcium channel blockers and cardiac mortality in the treatment of hypertension: a report from the Department of Health Hypertension Care Computing Project (DHCCP)","volume":"11","author":"Bulpitt","year":"1997","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0068|cit68","first-page":"835","article-title":"Enalapril and verapamil in the treatment of isolated systolic hypertension in the elderly","volume":"14","author":"Espinel","year":"1992","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/hc0402.102929","article-title":"Fosinopril versus Amlodipine Comparative Treatments Study: a randomized trial to assess effects on plasminogen activator inhibitor-1","volume":"105","author":"Pahor","year":"2002","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD003654.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","article-title":"The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients","volume":"23","author":"Liu","year":"2005","journal-title":"Journal of Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD003654.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1291\/hypres.18.235","article-title":"A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - The GLANT Study. Study Group on Long-term Antihypertensive Therapy","volume":"18","author":"The GLANT Study Group","year":"1995","journal-title":"Hypertension Research"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.CIR.95.8.2007","article-title":"Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension","volume":"95","author":"Gottdiener","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1475-2840-11-134","article-title":"Olmesartan\/amlodipine\/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study","volume":"11","author":"Kereiakes","year":"2012","journal-title":"Cardiovascular Diabetology"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1185\/030079903125001677","article-title":"Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine","volume":"19","author":"Kes","year":"2003","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/01.hjh.0000408153.50707.e8","article-title":"Renin-guided versus routine treatment in young untreated hypertension: a randomized comparative pilot study","volume":"29","author":"Kim","year":"2011","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/ndt\/gft034","article-title":"Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study","volume":"28","author":"Kojima","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0078|cit78","first-page":"S30","article-title":"Effects of manidipine and delapril on type 2 diabetic neuropathy. A randomized, double-blind, placebo-controlled trial (the DEMAND study)","volume":"17","author":"Lauria","year":"2012","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0079|cit79","first-page":"1094","article-title":"Efficacy and safety of enalapril versus extended-release nifedipine for the treatment of mild-to-moderate essential hypertension: A multicenter 22-week study","volume":"15","author":"Leon","year":"1993","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD003654.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/0002-8703(92)90283-2","article-title":"A comparison of the acute hypotensive effects of two different doses of nifedipine","volume":"124","author":"Maharaj","year":"1992","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD003654.pub5-BIB0081|cit81","first-page":"568","article-title":"Are all fixed dose combinations equally effective in blood pressure control? The analysis of four different fixed dose antihypertensive combinations","volume":"12","author":"Mesci","year":"2011","journal-title":"Obesity Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003654.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2012.326","article-title":"An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone","volume":"83","author":"Kim-Mitsuyama","year":"2013","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD003654.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1532-5415.1995.tb07393.x","article-title":"Long-term survival and use of antihypertensive medications in older persons","volume":"43","author":"Pahor","year":"1995","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0735-1097(97)00311-2","article-title":"Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial","volume":"30","author":"Papademetriou","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/hc3601.095927","article-title":"Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial","volume":"104","author":"Devereux","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jama.1995.03530080036038","article-title":"The risk of myocardial infarction associated with antihypertensive drug therapies","volume":"274","author":"Psaty","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0895-7061(98)00233-7","article-title":"Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension","volume":"12","author":"Radevski","year":"1999","journal-title":"American Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD003654.pub5-BIB0088|cit88","first-page":"265","article-title":"Captopril, nifedipine and their combination for therapy of hypertensive urgencies","volume":"80","author":"Schneider","year":"1991","journal-title":"South African Medical Journal"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/00004872-199610000-00013","article-title":"Shanghai trial of nifedipine in the elderly (STONE)","volume":"14","author":"Gong","year":"1996","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00004872-199816120-00016","article-title":"Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group","volume":"16","author":"Liu","year":"1998","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"287-302","DOI":"10.1007\/BF03324024","article-title":"Syst-Eur: a multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization","volume":"3","author":"Amery","year":"1991","journal-title":"Aging Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/01.HYP.32.3.410","article-title":"Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension","volume":"32","author":"Staessen","year":"1998","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/00005344-199512000-00020","article-title":"Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension","volume":"26","author":"Leeuwen","year":"1995","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0095|cit95","first-page":"139","article-title":"Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension","volume":"12","author":"Weir","year":"1990","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/01.hjh.0000408030.31614.74","article-title":"Chinese hypertension intervention efficacy (CHIEF) study: randomized controlled trial of initial combination CCB-based antihypertensive in patients with hypertension to reduce cardiovascular events","volume":"29","author":"Wen","year":"2011","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1097\/HJH.0b013e3283582eec","article-title":"Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial?","volume":"30","author":"Zhang","year":"2012","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0895-7061(04)00863-5","article-title":"Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects","volume":"17","author":"Angeli","year":"2004","journal-title":"American Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD003654.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1098-3597(04)80078-4","article-title":"Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials","volume":"6","author":"Black","year":"2004","journal-title":"Clinical Cornerstone"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomized trials","volume":"356","author":"Blood Pressure Lowering Treatment Trialists' Collaboration","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials","volume":"362","author":"Blood Pressure Lowering Treatment Trialists' Collaboration","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/CIRCULATIONAHA.113.008506","article-title":"Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study","volume":"130","author":"Cheng","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"9343","key":"10.1002\/14651858.CD003654.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(02)11403-6","article-title":"Selected major risk factors and global and regional burden of disease","volume":"360","author":"Ezzati","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/bmj.325.7365.652","article-title":"Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis","volume":"325","author":"Fergusson","year":"2002","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(15)00128-2","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Forouzanfar","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1742-1241.2008.01713.x","article-title":"Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk","volume":"62","author":"Haller","year":"2008","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/08037059209077502","article-title":"Prospective Randomized Open Blinded End-point (PROBE) study. A novel design for intervention trials","volume":"1","author":"Hansson","year":"1992","journal-title":"Blood Pressure"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0109|cit109","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0110|cit110","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available at handbook.cochrane.org"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0111|cit111","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available at handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD003654.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0002-8703(91)90432-H","article-title":"The epidemiology of impaired glucose tolerance and hypertension","volume":"121","author":"Kannel","year":"1991","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD003654.pub5-BIB0115|cit115","first-page":"1462","article-title":"2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"28","author":"Mancia","year":"2007","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/pcad.2000.7010","article-title":"Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies","volume":"43","author":"Opie","year":"2000","journal-title":"Progress in Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0735-1097(01)01728-4","article-title":"Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy","volume":"39","author":"Opie","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"9982","key":"10.1002\/14651858.CD003654.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0119|cit119","unstructured":"Reboussin DM Allen NB Griswold ME Guallar E Hong Y Lackland DT Systematic Review for the 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines Hypertension 10.1161\/HYP.0000000000000067"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0120|cit120","unstructured":"Ryan R Hill S How to GRADE the quality of the evidence Cochrane Consumers and Communication Group, available at cccrg.cochrane.org\/author-resources. Version 3.0. 1 December 2016"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0121|cit121","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and\u2018Summary of findings' tables Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0122|cit122","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00004872-200306000-00002","article-title":"Cardiovascular prevention and blood pressure reduction: a quantitative overview","volume":"21","author":"Staessen","year":"2003","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD003654.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2007.01.016","article-title":"Calcium channel antagonists: clinical uses - past, present and future","volume":"74","author":"Triggle","year":"2007","journal-title":"Biochemical Pharmacology"},{"issue":"12","key":"10.1002\/14651858.CD003654.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"Turnbull","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","article-title":"Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention","volume":"46","author":"Verdecchia","year":"2005","journal-title":"Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD003654.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"33","key":"10.1002\/14651858.CD003654.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD003654.pub5-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub2","article-title":"Beta-blockers for hypertension","author":"Wiysonge","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003654.pub5-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001841.pub3","article-title":"First-line drugs for hypertension","author":"Wright","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10017","key":"10.1002\/14651858.CD003654.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003654.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/01.hjh.0000170370.41387.1b","article-title":"Evidence-based medicine in hypertension: what type of evidence?","volume":"23","author":"Zanchetti","year":"2005","journal-title":"Journal of Hypertension"},{"issue":"8","key":"10.1002\/14651858.CD003654.pub5-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003654.pub4","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","author":"Chen","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9246","key":"10.1002\/14651858.CD003654.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(00)03306-7","article-title":"Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials","volume":"356","author":"Pahor","year":"2000","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003654.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T00:00:00Z","timestamp":1641686400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T06:18:32Z","timestamp":1639721912000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003654.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Hypertension Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":135,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003654.pub5","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD003654.pub6","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]}}}